VectorB2B
Full-service contract research organisation providing integrated preclinical, CMC and clinical development services. Capabilities include GLP and non-GLP in vivo toxicology, in vitro toxicology and genotoxicity testing, antibody discovery (including phage display and NGS selection analysis), preclinical PK/PD and bioanalysis, GMP biologics manufacturing, clinical trial management across phases I–IV and real-world evidence, and technology-enabled clinical data collection and trial operations. Operates BSL2 laboratory infrastructure and a manufacturing plant in Portugal and participates in European funding frameworks and research consortia.
Industries
N/A
Nr. of Employees
small (1-50)
Services
Antibody discovery, phage display, hit-to-lead and lead optimisation, supported by in vitro and in vivo efficacy and mechanism-of-action studies across multiple therapeutic areas.
Design and execution of GLP and non-GLP toxicology studies (acute, sub-acute, sub-chronic and chronic), safety pharmacology and genotoxicity testing aligned with regulatory test guidelines.
GMP-compliant manufacturing for biologic investigational medicinal products and clinical supply supported by established quality systems.
End-to-end clinical development services including study design, operations, monitoring, data management, biostatistics, medical writing, pharmacovigilance and regulatory support across interventional and observational studies.
Operational CRO support tailored for hospital investigational centres and clinical sites covering site feasibility, recruitment, TMF maintenance, monitoring, clinical sample management and accountability services.
Strategic portfolio consulting, reformulation and repurposing support, and integrated bench-to-bedside development planning across discovery, CMC, toxicology and clinical operations.
Antibody discovery, phage display, hit-to-lead and lead optimisation, supported by in vitro and in vivo efficacy and mechanism-of-action studies across multiple therapeutic areas.
Design and execution of GLP and non-GLP toxicology studies (acute, sub-acute, sub-chronic and chronic), safety pharmacology and genotoxicity testing aligned with regulatory test guidelines.
GMP-compliant manufacturing for biologic investigational medicinal products and clinical supply supported by established quality systems.
End-to-end clinical development services including study design, operations, monitoring, data management, biostatistics, medical writing, pharmacovigilance and regulatory support across interventional and observational studies.
Operational CRO support tailored for hospital investigational centres and clinical sites covering site feasibility, recruitment, TMF maintenance, monitoring, clinical sample management and accountability services.
Strategic portfolio consulting, reformulation and repurposing support, and integrated bench-to-bedside development planning across discovery, CMC, toxicology and clinical operations.
Expertise Areas
- Clinical trial management
- GLP in vivo toxicology
- GMP biologics manufacturing
- Antibody discovery and engineering
Key Technologies
- Next-generation sequencing (NGS)
- LC-MS/MS and UPLC/UHPLC bioanalysis
- Surface plasmon resonance (SPR)
- Isothermal titration calorimetry (ITC)
News & Updates
Symposium bringing together strategic and operational stakeholders to foster collaboration and innovation in clinical research in Portugal.
Participation at MICROBIOTEC’25, University of Azores, Ponta Delgada.
Guide describing how eligible beneficiaries can use EIC Access+ co-funding to procure specialised services from the Service Catalogue, including timelines, eligibility and practical considerations for drug development services.
Series of articles covering clinical trial outsourcing, operational bottlenecks in hospital-based research and the role of specialised CRO execution.
Article describing principles and applications of xenograft models in preclinical oncology research.
Analysis of the operational and regulatory role of CROs in clinical research execution.
Symposium bringing together strategic and operational stakeholders to foster collaboration and innovation in clinical research in Portugal.
Participation at MICROBIOTEC’25, University of Azores, Ponta Delgada.
Guide describing how eligible beneficiaries can use EIC Access+ co-funding to procure specialised services from the Service Catalogue, including timelines, eligibility and practical considerations for drug development services.
Series of articles covering clinical trial outsourcing, operational bottlenecks in hospital-based research and the role of specialised CRO execution.
Article describing principles and applications of xenograft models in preclinical oncology research.
Analysis of the operational and regulatory role of CROs in clinical research execution.